-3 to 41 6 IU/1), p<0 001, df=27, t=9-0; luteinising hormone: mean change 10-3 IU/l (6-1 to 14-6 IU/1), p<0 001, df=27, t=5-0).
Mean oestradiol concentrations after two and four months oftreatment did not differ significantly between the two groups. Mean follicle stimulating hormone and luteinising hormone concentrations were significantly higher in the patch group at two months (p<0001) and four months (p<005). Preoperatively none of the patients complained of hot flushes. After four months of treatment two of the 12 patients in the patch group and three of the 16 in the implant group complained of hot flushes.
Comment
Although recommended starting doses were selected in this study, the 0-05 mg patch and 50 mg implant were not equivalent in terms of hormone profiles; in terms of preventing hot flushes, however, they were equally effective. Hormone concentrations are not routinely measured in patients receiving oestrogen replacement, so this difference in hormone profiles would go undetected. 
